TRCT
JSPR icon

Tower Research Capital (TRC)’s Jasper Therapeutics JSPR Stock Holding History

Tower Research Capital (TRC)’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.93K Buy
9,336
+3,031
+48% +$2.27K ﹤0.01% 4452
2026
Q1 		$5.52K Buy
6,305
+5,164
+453% +$7.17K ﹤0.01% 4110
2025
Q4 		$2.09K Buy
1,141
+1,140
+114,000% +$2.29K ﹤0.01% 4587
2025
Q3 		$2 Sell
1
-3,746
-100% -$11.4K ﹤0.01% 5189
2025
Q2 		$20.8K Buy
3,747
+1,259
+51% +$6.2K ﹤0.01% 3658
2025
Q1 		$10.7K Buy
2,488
+933
+60% +$6.21K ﹤0.01% 3613
2024
Q4 		$33.2K Buy
1,555
+860
+124% +$17.9K ﹤0.01% 2829
2024
Q3 		$13.1K Buy
+695
New +$13.8K ﹤0.01% 3544
2024
Q1 		– Sell
-1,114
Closed -$8.79K – 6017
2023
Q4 		$8.79K Buy
+1,114
New +$7.48K ﹤0.01% 4463
2023
Q3 		– Sell
-940
Closed -$12.9K – 6097
2023
Q2 		$12.9K Buy
+940
New +$14K ﹤0.01% 3823
2023
Q1 		– Sell
-1,284
Closed -$6K – 6069
2022
Q4 		$6K Sell
1,284
-84
-6% -$562 ﹤0.01% 4731
2022
Q3 		$11K Buy
1,368
+907
+197% +$16.6K ﹤0.01% 4447
2022
Q2 		$9K Buy
461
+325
+239% +$9.26K ﹤0.01% 4566
2022
Q1 		$5K Sell
136
-155
-53% -$6.99K ﹤0.01% 5061
2021
Q4 		$23K Sell
291
-604
-67% -$56.5K ﹤0.01% 3515
2021
Q3 		$92K Buy
895
+890
+17,800% +$90.9K ﹤0.01% 2469
2021
Q2 		$1K Hold
5
– – ﹤0.01% 5215
2021
Q1 		$1K Sell
5
-35
-88% -$3.56K ﹤0.01% 5187
2020
Q4 		$4K Buy
+40
New +$3.98K ﹤0.01% 4718
2020
Q3 		– Hold
0
– – – 4955

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Tower Research Capital (TRC)'s JSPR Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Jasper Therapeutics (JSPR) stake by 48% in Q2 2026, buying an estimated $2.27K and bringing the position to 9,336 shares worth $3.93K. The position accounts for ﹤0.01% of the portfolio, ranked #4452.

Tower Research Capital (TRC) first reported a position in JSPR in Q4 2020 and has held it in 19 quarters since. The position peaked at $92K in Q3 2021. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • Tower Research Capital (TRC) held 9,336 shares of Jasper Therapeutics worth $3.93K as of Q2 2026.
  • Tower Research Capital (TRC) bought 3,031 Jasper Therapeutics shares in Q2 2026, an estimated $2.27K.
  • Jasper Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4452 holding.
  • Tower Research Capital (TRC) first reported a position in Jasper Therapeutics in Q4 2020 and has held it in 19 quarters since.
  • Tower Research Capital (TRC)'s Jasper Therapeutics position peaked at $92K in Q3 2021.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.